1-15 of 443
The Metabolic Roots of Early-Onset Colorectal Cancer
Project Oncology®The Metabolic Roots of Early-Onset Colorectal Cancer
MASLD Explained: A Modern Framework for a Multisystem Condition
Clinician's RoundtableMASLD Explained: A Modern Framework for a Multisystem Condition
Unveiling the Role of Obesity in MASLD Progression
Clinician's RoundtableUnveiling the Role of Obesity in MASLD Progression
New Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
Clinician's RoundtableNew Insights into VKD: Exploring Maternal Obesity and Neonatal Vitamin K Status
From Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Clinician's RoundtableFrom Gut Microbe to Metabolic Modulator: The Potential Role of R. hominis in Obesity
Assessing the Role of Metabolic Factors in Psoriasis Management
AudioAbstractsAssessing the Role of Metabolic Factors in Psoriasis Management
- advertisement
Finerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Heart MattersFinerenone for CKD in Type 1 Diabetes: Updates from FINE-ONE
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
AIP Emerges as a Potential Marker for Diabetic Kidney Risk
Clinician's RoundtableAIP Emerges as a Potential Marker for Diabetic Kidney Risk
- advertisement
Pediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
On the Frontlines of PsoriasisPediatric Psoriasis in Focus: Emerging Insights on Immune and Obesity Drivers
Linking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Clinician's RoundtableLinking Obesity to Alzheimer’s: The Lipid Signals Driving Neurodegeneration
Screening for Prediabetes in Youth with Obesity: Evaluating the TyG Index
Clinician's RoundtableScreening for Prediabetes in Youth with Obesity: Evaluating the TyG Index
